/
41
Pipeline Programs↗
138
Active Trials↗
23
Companies Involved↗
HIV is a moderately active landscape with 41 programs across 23 companies. The most active players are Incyte, Jiangsu Hansoh Pharmaceutical Co., Ltd., GSK. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 110
CAB LA
GSK
DV201P-RNA
National Institute of Allergy and Infectious Diseases (NIAID)
DV202B1-RNA
National Institute of Allergy and Infectious Diseases (NIAID)
Epgt121v1-LS (IV)
National Institute of Allergy and Infectious Diseases (NIAID)
Epgt121v1-LS (SC)
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 211
Maraviroc
GSK
PGDM1400LS
National Institute of Allergy and Infectious Diseases (NIAID)
VRC07-523LS
National Institute of Allergy and Infectious Diseases (NIAID)
PGT121.414.LS
National Institute of Allergy and Infectious Diseases (NIAID)
Dendritic Cell Vaccine
H. Lee Moffitt Cancer Center and Research Institute
Phase 39
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
27 of 29 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 83% of 41 pipeline programs.
Analysis
Trial Status
379
clinical trials
Completed204 · 54%
Recruiting61 · 16%
Not yet recruiting42 · 11%
Active, not recruiting30 · 8%
Unknown status15 · 4%
Terminated13 · 3%
Other14 · 4%
Clinical Trials
Trial Activity
379 trials
Procedures to Obtain Plasma, Lymphocytes, or Other Specimens for Research Studies
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00114647·3,000 enrolled
Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02154035·130 enrolled
An Evaluation of HIV-associated Neurocognitive Disorders (HAND) in Virologically Controlled Patients
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT01875588·1,150 enrolled
Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00029445·500 enrolled
A Nonrandomized Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07569029·42 enrolled
Page 1 of 26
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)